PTG-300
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
β-thalassemia
Conditions
β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia
Trial Timeline
Dec 19, 2018 → Jul 31, 2020
NCT ID
NCT03802201About PTG-300
PTG-300 is a phase 2 stage product being developed by Protagonist Therapeutics for β-thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03802201. Target conditions include β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04767802 | Phase 2 | Completed |
| NCT04516382 | Phase 1 | Completed |
| NCT04202965 | Phase 2 | Completed |
| NCT04054921 | Phase 2 | Completed |
| NCT03802201 | Phase 2 | Completed |
Competing Products
8 competing products in β-thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| luspatercept | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 1 | 33 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Luspatercept | Bristol Myers Squibb | Pre-clinical | 22 |
| Luspatercept | Bristol Myers Squibb | Pre-clinical | 22 |
| PTG-300 | Protagonist Therapeutics | Phase 2 | 49 |